Search research articles
Contact Us
Filters
Showing results (61-70 of 92) with videos related to
Page
of 10
Sort By:
Journal of Cancer Research and Clinical Oncology
|
December 30, 2025
Subgroup analyses of the phase 3 FOCUS study of melphalan/hepatic delivery system in patients with unresectable metastatic uveal melanoma
Jonathan S Zager, Marlana Orloff, Pier Francesco Ferrucci, et al.
NEJM Evidence
|
February 6, 2024
Overall Survival and Response with Nivolumab and Relatlimab in Advanced Melanoma
Georgina V Long, F Stephen Hodi, Evan J Lipson, et al.
The Lancet. Oncology
|
March 13, 2017
Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial
Reinhard Dummer, Dirk Schadendorf, Paolo A Ascierto, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 22, 2022
Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination
Ana Arance, Luis de la Cruz-Merino, Teresa M Petrella, et al.
Nature Communications
|
December 2, 2021
Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial
Maria Gonzalez-Cao, Clara Mayo de Las Casas, Juana Oramas, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 24, 2018
Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study
Sara Valpione, Matteo S Carlino, Johanna Mangana, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 14, 2022
Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for <i>BRAF</i> V600-Mutant Unresectable or Metastatic Melanoma
Reinhard Dummer, Georgina V Long, Caroline Robert, et al.
Future Oncology (London, England)
|
October 6, 2022
SOLTI-1904 ACROPOLI TRIAL: efficacy of spartalizumab monotherapy across tumor-types expressing high levels of <i>PD1</i> mRNA
Aleix Prat, Luis Paz-Ares, Manel Juan, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 22, 2015
Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma
Dirk Schadendorf, Mayur M Amonkar, Daniil Stroyakovskiy, et al.
The New England Journal of Medicine
|
January 5, 2022
Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma
Hussein A Tawbi, Dirk Schadendorf, Evan J Lipson, et al.
Page
of 10
Search research articles
Search
Showing results (61-70 of 92) with videos related to
Sort By:
Page
of 10
Journal of Cancer Research and Clinical Oncology
|
December 30, 2025
Subgroup analyses of the phase 3 FOCUS study of melphalan/hepatic delivery system in patients with unresectable metastatic uveal melanoma
Jonathan S Zager, Marlana Orloff, Pier Francesco Ferrucci, et al.
NEJM Evidence
|
February 6, 2024
Overall Survival and Response with Nivolumab and Relatlimab in Advanced Melanoma
Georgina V Long, F Stephen Hodi, Evan J Lipson, et al.
The Lancet. Oncology
|
March 13, 2017
Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial
Reinhard Dummer, Dirk Schadendorf, Paolo A Ascierto, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 22, 2022
Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination
Ana Arance, Luis de la Cruz-Merino, Teresa M Petrella, et al.
Nature Communications
|
December 2, 2021
Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial
Maria Gonzalez-Cao, Clara Mayo de Las Casas, Juana Oramas, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 24, 2018
Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study
Sara Valpione, Matteo S Carlino, Johanna Mangana, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 14, 2022
Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for <i>BRAF</i> V600-Mutant Unresectable or Metastatic Melanoma
Reinhard Dummer, Georgina V Long, Caroline Robert, et al.
Future Oncology (London, England)
|
October 6, 2022
SOLTI-1904 ACROPOLI TRIAL: efficacy of spartalizumab monotherapy across tumor-types expressing high levels of <i>PD1</i> mRNA
Aleix Prat, Luis Paz-Ares, Manel Juan, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 22, 2015
Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma
Dirk Schadendorf, Mayur M Amonkar, Daniil Stroyakovskiy, et al.
The New England Journal of Medicine
|
January 5, 2022
Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma
Hussein A Tawbi, Dirk Schadendorf, Evan J Lipson, et al.
Page
of 10